Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$377.85 - $519.88
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.15M
Market Cap
$118.08B
Enterprise Value$115.05B
Total Cash (Recent Filing)$6.20B
Total Debt (Recent Filing)$1.65B
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 04, 2025EPS Estimate
4.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.06
Shares Outstanding256,797,180
10 Day Avg. Volume1,029,507
30 Day Avg. Volume1,146,367
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)7.16
Price to Sales (P/S)0.00
P/FCF Ratio-93.86
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit12.05
Enterprise Value/Ebitda82.69
Forecast
1Y Price Target
$514.89Price Target Upside12.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Vertex Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe potential for VX-993 to be more efficacious due to the ability to be dosed higher compared to Journavx is seen as a positive factor.
Market PerformancePositive uptake trend of Journavx has been indicated by a survey, showing more than doubling of scripts and improvements in reimbursement.
Product LaunchVertex management is taking all possible steps to create the conditions for a successful launch in acute pain, focusing on securing broad coverage, ensuring strong physician awareness, and ensuring patient scripts are filled by ensuring product is available at the pharmacy.
Bears Say
Clinical Trial ResultsThe failure of VX-993 to show statistical significance versus placebo, or if it shows a placebo-adjusted SPID48 of less than 29, could negatively affect the stock.
Market DynamicsThe rate of switching to Alyftrek has been slower than expected due to new liver monitoring requirements.
Sales PerformanceThe July 4th holiday week drove some modest script declines as investors look to 2Q earnings - TRx -10% WoW for 7/4/25, finishing the week at 5,183 vs. 5,754 the week prior.
Ownership Overview
0.22% Insiders
37.82% Mutual Funds
0.54% Other Institutional Investors
35.79% Public Companies and Individual Investors
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $377.85 and its highest was $519.88 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $118.08B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Aug 04, 2025 which is in 12 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on May 05, 2025. The company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.245 by -$0.185.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.27.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 256,797,180 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.06 in its last earnings report, missing expectations of $4.245. Following the earnings report the stock price went down -10.028%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
Vertex Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$514.89 (12.30% Upside)
$514.89 (12.30% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 95%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 228.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.79%
12-Months-Change
Fundamentals
Return on Equity
-5.64%
Trailing 12-Months
Asset Growth
-4.34%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX Company Deck
VRTX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Vertex Pharmaceuticals demonstrated strong revenue growth and successful product launches in the U.S., but faced challenges with ex-U.S. revenue decline and increased operating expenses. The pipeline is advancing well with multiple programs in pivotal development, although the temporary pause in the VX-522 study represents a setback. Financial guidance for the year was raised, reflecting confidence in continued growth.Read More>VRTX Revenue Breakdown
60.66% U.S.
39.34% Europe
VRTX Stock 12 Month Forecast
Average Price Target
$514.89
▲(12.30%Upside)